Report of Foreign Issuer (6-k)
10 Februar 2020 - 8:49PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of February 2020
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in
its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
____
The press release attached to this Form
6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and
Form F-3 (File Nos. 333-195124, 333-204795, 333-209037 and 333-220644), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On February 10, 2020, Can-Fite BioPharma Ltd. announced the
pricing of a public offering of 3,333,334 units at a price to the public of $1.50 per unit. A copy of this press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: February 10, 2020
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
Von Mai 2023 bis Mai 2024